Evidence map›Paper›PMID 41505128›Full record

ArticleJAMA network open2026

Risk of Household Secondary Invasive Group A Streptococcal Infections After a Prophylaxis Policy Change.

Brechje de Gier, Bart J M Vlaminckx, Annika van Roon, Mirjam J Knol, Margreet J M Te Wierik, Daan W Notermans, Hester E de Melker, Nina M van Sorge

Abstract read
In one paragraph

Article in JAMA network open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Brechje de GierCenter for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands.
Bart J M VlaminckxDepartment of Medical Microbiology, University Medical Center Utrecht, Utrecht, the Netherlands.
Annika van RoonCenter for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands.
Mirjam J KnolCenter for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands.
Margreet J M Te WierikCenter for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands.
Daan W NotermansCenter for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands.
Hester E de MelkerCenter for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands.
Nina M van SorgeDepartment of Medical Microbiology and Infection Prevention, Amsterdam University Medical Center location AMC, University of Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam, the Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Importance: Household contacts of patients with invasive group A streptococcus (iGAS) disease have an increased risk of iGAS. In the Netherlands, the iGAS public health policy was changed in January 2023, offering antibiotic prophylaxis to household contacts of all patients with iGAS rather than only those presenting with necrotizing fasciitis or streptococcal toxic shock syndrome. Objective: To estimate risk of iGAS in the general population and among household and other contacts of primary patients with iGAS, before and after the policy change. Design, Setting, and Participants: This nationwide, population-based, open cohort study, linked population registry data with iGAS laboratory data for the study period (April 2022 to December 2024). The study population consisted of all persons included in the Dutch population registry at any time during the study period. The case definition was an iGAS isolate submitted to the Netherlands Reference Laboratory for Bacterial Meningitis, with disease onset in the study period. Exposure: For contacts of primary patients with iGAS, exposure risk period was defined as the 30 days after culture date of the index patient. Exposure under the new policy was defined as all person-time after January 20, 2023. Main Outcomes and Measures: Incidence rate ratios (IRR) of iGAS during the 30-day risk period compared with unexposed person-time were estimated. Secondary attack rates among household contacts were estimated with an odds ratio (OR) to compare attack rates before and after the policy change. Estimates were adjusted for age group, sex, household socioeconomic status, and year quarter. Results: A total of 19 006 247 persons (9 467 251 male [49.8%]; 6 308 794 [33.2%] aged 20-45 years) contributed 51 067 977 person-years to the analysis. A total of 3644 iGAS isolates from 3630 unique persons were included, of which 14 were household secondary cases. The IRR for household contacts during the risk period was 235.25 (95% CI, 94.35-586.59) before and 74.00 (95% CI, 35.17-155.71) after the policy change, compared with unexposed person-time. The secondary attack rate among household contacts was 0.219% (7 individuals) before and 0.047% (7 individuals) after the policy change (adjusted OR, 0.17; 95% CI, 0.03-0.83). Conclusions and Relevance: In this nationwide cohort study, there was a reduction in secondary iGAS risk among household contacts after implementation of an expanded antibiotic prophylaxis policy, which suggests that antibiotic prophylaxis for household contacts of patients with iGAS prevents secondary iGAS infection.

Indexed as

Antibiotic ProphylaxisHealth PolicyStreptococcal InfectionsStreptococcus pyogenesAdolescentAdultAgedChildChild, PreschoolCohort StudiesFamily CharacteristicsFemaleHumansIncidenceInfantMale

Identifiers

PMID41505128
PMCPMC12784225

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.